Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $4.92 Consensus Target Price from Analysts

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have earned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $4.9167.

Several equities research analysts have recently issued reports on VVOS shares. Ascendiant Capital Markets lowered their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a report on Wednesday, December 3rd. HC Wainwright began coverage on shares of Vivos Therapeutics in a report on Monday, November 17th. They set a “buy” rating and a $7.00 price target on the stock. Zacks Research raised shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 1st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, October 8th.

Institutional Trading of Vivos Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Connective Capital Management LLC purchased a new stake in shares of Vivos Therapeutics during the third quarter valued at $620,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics in the 2nd quarter worth about $220,000. Finally, XTX Topco Ltd bought a new stake in Vivos Therapeutics during the 2nd quarter valued at about $65,000. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Price Performance

Shares of Vivos Therapeutics stock opened at $2.07 on Friday. The stock has a market cap of $18.61 million, a price-to-earnings ratio of -1.17 and a beta of 6.88. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.78 and a current ratio of 0.78. The stock has a 50 day moving average price of $2.54 and a 200-day moving average price of $3.47. Vivos Therapeutics has a one year low of $1.98 and a one year high of $7.95.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings results on Wednesday, November 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The company had revenue of $6.78 million during the quarter, compared to the consensus estimate of $4.49 million. Vivos Therapeutics had a negative return on equity of 351.28% and a negative net margin of 98.77%. Equities analysts expect that Vivos Therapeutics will post -1.79 EPS for the current year.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.